Stock listing
A3C7A5 Stock Price, News, Filings & Events — Maat Pharma
Selected listing: A3C7A5 · LS · EUR · DE
This page tracks Maat Pharma's A3C7A5:LS listing on LS in EUR for DE, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following A3C7A5:LS. A3C7A5:LS is the stock-level entry point for investors researching Maat Pharma, while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary.
- Ticker
- A3C7A5:LS
- Asset type
- Stock
- Market cap
- $61.1M
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- Exchange
- LS
- Currency
- EUR
Maat Pharma A3C7A5:LS stock context
This page tracks Maat Pharma's A3C7A5:LS listing on LS in EUR for DE, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following A3C7A5:LS. A3C7A5:LS is the stock-level entry point for investors researching Maat Pharma, while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary.
Latest news from Maat Pharma
MaaT Pharma Presents the Results of its Annual General Meeting and Provides a Statement on its Half-Year Liquidity Contract
July 6, 2026
MaaT Pharma Announces Plan to Request Re-Examination Following Negative CHMP Opinion for MaaT013 for the treatment of acute Graft-versus-...
June 29, 2026
MaaT Pharma Provides Business Update and Reports Financial Results for the First Quarter 2026
May 26, 2026
MaaT Pharma Announces Provides an Update on the Application for Marketing Authorization of MaaT013 in the treatment of acute Graft-versus...
May 21, 2026
MaaT Pharma Provides an Update on the Application for Marketing Authorization of MaaT013 (Xervyteg®) in the treatment of acute Graft-vers...
May 20, 2026
Research Maat Pharma
Maat Pharma investor report
Review AI stock analysis and investor report context for A3C7A5:LS.
Maat Pharma company profile
View the public company page for Maat Pharma on 6ix.
Maat Pharma news
Read company news and market updates connected to Maat Pharma.
Maat Pharma investor events
Find investor webinars, events, and replay context for Maat Pharma.
Alternate listings
MAAT:EURONEXT
FR · EUR
Alternate listing for Maat Pharma; the primary context on this page is A3C7A5:LS.
4RD:GETTEX
DE · EUR
Alternate listing for Maat Pharma; the primary context on this page is A3C7A5:LS.
A3C7A5:LSX
DE · EUR
Alternate listing for Maat Pharma; the primary context on this page is A3C7A5:LS.
4RD:FWB
DE · EUR
Alternate listing for Maat Pharma; the primary context on this page is A3C7A5:LS.
MATPF:OTC
US · USD
Alternate listing for Maat Pharma; the primary context on this page is A3C7A5:LS.
4RD:HAM
DE · EUR
Alternate listing for Maat Pharma; the primary context on this page is A3C7A5:LS.
4RD:MUN
DE · EUR
Alternate listing for Maat Pharma; the primary context on this page is A3C7A5:LS.
4RD:SWB
DE · EUR
Alternate listing for Maat Pharma; the primary context on this page is A3C7A5:LS.
4RD:DUS
DE · EUR
Alternate listing for Maat Pharma; the primary context on this page is A3C7A5:LS.